When patients and clinicians alike consider genome sequencing, an attitude of "more is better" often predominates notions of what information to obtain. But new perspectives on the comparative value and contained costs of more refined exome sequencing have since emerged. Joining host Dr. Robert Green to discuss the benefits and drawbacks of respective clinical sequencing options is Dr. Richard Gibbs, Wofford Cain Chair and Professor of Molecular and Human Genetics, as well as Founder and Director of the Human Genome Sequencing Center at Baylor College of Medicine.
